DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Lung Cancer
  4. Research Highlights/News
  5. 2022 Lung Cancer Research Program

Lung Cancer

NEWS RELEASE

Released: January 14, 2022

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Lung Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)

The FY22 Defense Appropriations Bill has not been signed into law. Although FY22 funds have not been appropriated for the Lung Cancer Research Program (LCRP), the LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the government.

The FY22 Defense Appropriations Act is anticipated to provide funding for the LCRP to support innovative, high-impact lung cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the Government. The FY22 LCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released. 

Applications submitted to the FY22 LCRP must address one or more of the following Areas of Emphasis: 

  • Identify innovative strategies for the prevention of the occurrence of lung cancer.
  • Identify innovative strategies for the screening and early detection of lung cancer.
  • Understand the molecular mechanisms of initiation and progression to lung cancer.
  • Understand contributors to lung cancer development other than tobacco.
  • Identify innovative strategies for the treatment of lung cancer.
  • Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
  • Develop or optimize biomarkers to assist with therapeutic decision-making.
  • Understand mechanisms of resistance to treatment (primary and secondary).
  • Identify innovative strategies for comprehensive lung cancer care (clinical management/surveillance/symptom management/palliative care).
  • Understand factors and/or develop implementation strategies to address health disparities in lung cancer.

Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service Members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY22 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health: 

  • Use of military of Veteran populations, biospecimens, data/databases, or programs in the proposed research.
  • Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators.
  • Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population.
  • Explanation of how the project addresses an aspect of lung cancer that has a direct relevance to military Service Members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco.
Award Mechanism Eligibility Key Mechanism Elements Funding
Concept Award Investigators at all academic levels.
  • Supports highly innovative, non-incremental, high risk/potentially high-reward lung cancer research.
  • Emphasis on innovation.
  • Clinical trials are not allowed.
  • Preliminary data are not required.
  • Relevance to military health is strongly encouraged.

    • New Options for FY22
  • Care Delivery and Health Disparity category must address one or both of the Care Delivery and/or Health Disparity Areas of Emphasis.
  • Cancer Research Continuum category must address at least one or more of the eight cancer continuum focused Areas of Emphasis.
  • Maximum funding of $100,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 1 year.
Career Development Award Principal Investigator: Independent investigators at the level of Assistant Professor, Instructor, or equivalent must be within 5 years of first faculty appointment.

Mentor: At or above the level of Associate Professor (or equivalent); have a proven publication and funding record in lung cancer research.
  • Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.
  • Clinical trials are not allowed.
  • Preliminary data are not required.
  • Relevance to military health is strongly encouraged.
  • Maximum funding of $250,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 2 years.
Idea Development Award Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) or

New Investigators: Investigators that meet the following criteria by the application submission deadline date:
  • Have not previously received an LCRP Idea Development Award or Early Investigator Synergistic Idea Award
  • Are within 10 years of first faculty appointment (or equivalent)
  • Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
  • Emphasis on innovation and impact.
  • New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
  • Clinical trials are not allowed.
  • Preliminary data are required.
  • Relevance to military health is strongly encouraged.
  • Maximum funding of $350,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 2 years.
Investigator-Initiated Translational Research Award Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations.
  • This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:
    • Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts
    • Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug application submission
    • Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials
  • Preliminary lung cancer relevant data are required.
  • Relevance to military health is strongly encouraged.
  • Maximum funding of $600,000 in direct costs (plus indirect costs).
  • Period of performance should not exceed 3 years.
Clinical Translational Research Partnership Award Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports translational studies that include an interventional clinical trial.
  • This mechanism is intended to fund partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications.
    • One partner is strongly encouraged to be from either a military treatment facility or a VA medical center.
  • Non-traditional partnerships are encouraged.
  • Preliminary lung cancer relevant data are required.
  • Relevance to military health is strongly encouraged.
  • Patient research advocate involvement is encouraged.
  • Maximum combined funding of $1,200,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Friday, January 14, 2022